Bullous pemphigoid (BP), which has no FDA-approved ... is the first biologic drug to show an improvement in remission and symptoms in BP, and the first to allow patients to reduce the use of ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition ... with no relapse, and standard treatment with oral corticosteroids had been tailed off without the need for any ...

such as Dupixent for the treatment of adults with bullous pemphigoid as discussed in this press release as well as chronic pruritus of unknown origin, lichen simplex chronicus, and other potential ...

“People with bullous pemphigoid live with unrelenting itch, blisters and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA ...

Dupixent was previously granted Orphan Drug Designation by the FDA for BP, which applies to investigational medicines intended for the treatment ... unknown origin, bullous pemphigoid, and lichen ...